AzurRx BioPharma Inc (NASDAQ:AZRX) Expected to Announce Earnings of -$0.22 Per Share

Brokerages expect AzurRx BioPharma Inc (NASDAQ:AZRX) to announce earnings of ($0.22) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for AzurRx BioPharma’s earnings, with the lowest EPS estimate coming in at ($0.26) and the highest estimate coming in at ($0.19). AzurRx BioPharma also reported earnings of ($0.22) per share in the same quarter last year. The business is scheduled to issue its next earnings results on Friday, August 9th.

According to Zacks, analysts expect that AzurRx BioPharma will report full-year earnings of ($0.77) per share for the current financial year, with EPS estimates ranging from ($0.85) to ($0.69). For the next year, analysts forecast that the company will post earnings of ($0.66) per share, with EPS estimates ranging from ($0.79) to ($0.43). Zacks’ EPS averages are an average based on a survey of analysts that cover AzurRx BioPharma.

AzurRx BioPharma (NASDAQ:AZRX) last released its quarterly earnings data on Wednesday, May 15th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.08).

A number of equities analysts have recently weighed in on AZRX shares. HC Wainwright set a $3.00 price objective on McEwen Mining and gave the stock a “buy” rating in a research note on Friday, May 24th. Maxim Group reaffirmed a “buy” rating and issued a $315.00 price objective (up previously from $305.00) on shares of Domino’s Pizza in a research note on Wednesday, April 24th. Finally, National Securities started coverage on AzurRx BioPharma in a research note on Tuesday, June 11th. They issued a “buy” rating and a $9.00 price objective for the company. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $7.58.

A number of institutional investors have recently made changes to their positions in AZRX. 683 Capital Management LLC boosted its stake in AzurRx BioPharma by 73.9% during the fourth quarter. 683 Capital Management LLC now owns 695,504 shares of the company’s stock valued at $842,000 after buying an additional 295,504 shares during the last quarter. Waldron Private Wealth LLC bought a new position in AzurRx BioPharma during the first quarter valued at approximately $169,000. Finally, Regentatlantic Capital LLC bought a new position in AzurRx BioPharma during the first quarter valued at approximately $48,000. 13.12% of the stock is owned by institutional investors.

Shares of NASDAQ AZRX remained flat at $$1.04 during mid-day trading on Friday. The stock had a trading volume of 368 shares, compared to its average volume of 354,523. The company has a market cap of $27.14 million, a P/E ratio of -1.18 and a beta of 2.23. The stock has a 50 day simple moving average of $1.53. AzurRx BioPharma has a 1 year low of $0.91 and a 1 year high of $3.75.

AzurRx BioPharma Company Profile

AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.

See Also: What is a Call Option?

Get a free copy of the Zacks research report on AzurRx BioPharma (AZRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.